## Coagadex
- **BPL**

- **Coagadex** is contraindicated in patients who have had life-threatening hypersensitivity reactions to COAGADEX or any of the components.
- Patients with a history of anaphylactic or severe systemic reactions to human plasma-derived products may have a decreased risk of similar reactions when treated with COAGADEX.

### Contraindications
- Life-threatening hypersensitivity reactions to COAGADEX or COAGADEX® are contraindicated in patients who have had anaphylactic or severe systemic reactions to human plasma-derived products.

### Viral Safety Processes
- **1.** Solvent/detergent treatment
- **2.** A 15-nm filtration
- **3.** Terminal dry heat treatment
- Using these steps, the actual amount of TRETTEN® in international units (IU) is stated on each carton and vial. Each vial contains 667-1042 IU of recombinant coagulation factor VIII prophylactically.

### Product Half Life
- **30.0 hours**
- Mean (SD); 7.1 (1.3) days

### Product Recovery Percentage
- **2.0%**

### Manufacturing Method
- Manufactured from cryo-depleted plasma into an albumin precipitate, which is then purified by chromatographic methods.

### Storage Requirements
- **Store COAGADEX in its original package to protect from light.**
- **Refrigeration at 2°C - 8°C (36°F - 46°F) for up to 30 days.**

### Shelf Life from Date of Manufacture
- **30 months**

### How Supplied / Diluent Volume
- **250 mL, 2.5 mL, or 500 mL vials**

### Indications
- **Indicated for the treatment of bleeding episodes in adults with acquired hemophilia A.**
- **Indicated for routine prophylaxis and peri-operative management in adults and children with hemophilia A or B with inhibitors.**
- **Congenital Factor VIII (FVIII) deficiency and**
- **Gammopathy thromboembolism with risk/benefit to patients.**

### Concomitant Use
- **Continuous or intermittent hemodialysis**
- **Continuous or intermittent peritoneal dialysis**

### Dosage and Administration
- **For the treatment of bleeding episodes**
- **For prophylaxis and peri-operative management**
- **For chronic or episodic hemophilia A**
- **For platelet transfusions, with or without antibodies**

### Additional Factor Products
- **Corifact Novo Nordisk**
- **Tretten Novo Nordisk**
- **OBIZUR Shire**
- **NovoSeven® RT Novo Nordisk**
- **Felba NF Shire**

### DISCLAIMER: Information provided herein is a summary of available information only. This summary has been compiled by BDI Pharma and does not represent a clinical comparison conducted by any manufacturer referenced from specific product brands, etc., should be a thorough review of appropriate clinical data. For a copy of a package insert or to request any additional information at our disposal, please contact us at 1-800-948-9834.

**NovoSeven® RT (1,000 micrograms/mL).**

**FEIBA is an Anti-Inhibitor Coagulant Complex indicated for use in hemophilia A and B patients with inhibitors for:**
- **Control and prevention of bleeding episodes**
- **Regular prophylaxis to prevent or reduce the frequency of bleeding episodes.**

**DISCLAIMER: Information provided herein is a summary of available information only. This summary has been compiled by BDI Pharma and does not represent a clinical comparison conducted by any manufacturer referenced from specific product brands, etc., should be a thorough review of appropriate clinical data. For a copy of a package insert or to request any additional information at our disposal, please contact us at 1-800-948-9834.**